Sign In
Buy IUGNF
$0.0650
-0.0350 (-35.00%)
At Close: Jul 31, 2026
Shares slide after Mkango Resources completes £12.5m fundraise, but oversubscription signals longer-term confidence
06:51am, Wednesday, 01'st Apr 2026
The AIM-listed rare earths company upsized its placing after strong demand, though shares fell back on dilution concerns. Shares in Mkango Resources Ltd...
Imugene launches $20M capital raise to advance azer-cel clinical program
12:54pm, Wednesday, 11'th Mar 2026
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has launched a capital raising of up to $20 million through a combination of an institutional placement and a...
Premier African Minerals falls 8% as emergency fundraise highlights Zulu project strain
06:02am, Wednesday, 11'th Mar 2026
Shares in Premier African Minerals Ltd (AIM:PREM, OTC:PRMMF), the AIM-listed mining company whose stock has lost more than 80% of its value over the past...
Imugene highlights azer-cel progress as trial patient enters remission
11:57am, Tuesday, 10'th Mar 2026
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) is drawing fresh attention to its experimental cancer therapy azer-cel after a Channel 10 news report highlighted...
Imugene reports strong early response rates for azer-cel in lymphoma study
07:28am, Tuesday, 10'th Mar 2026
Clinical-stage immuno-oncology company Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has reported encouraging early response rates from the CAR T-naïve cohort...
Rathbones upgraded to 'buy' as new CEO sets out plan to become the UK's best wealth manager
07:01am, Friday, 27'th Feb 2026
Panmure Liberum lifts its target price from 2100p to 2600p, arguing the market is still pricing in the old Rathbones, not the one Jonathan Sorrell intends...
Imugene to showcase azer-cel data at major US healthcare conference
05:34am, Friday, 27'th Feb 2026
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) will present updated clinical data on its lead cell therapy program at one of the world’s largest healthcare...
Imugene secures $2.7m R&D tax refund to support clinical programs
08:14am, Wednesday, 25'th Feb 2026
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has received a nearly A$2.74 million research and development tax refund for the 2025 financial year, bolstering...
Nasdaq drops for third straight week as gold and silver tank
11:22am, Friday, 30'th Jan 2026
4:20pm: Metals rally collapses Stocks slipped on Friday as investors digested President Trump’s announcement that he will nominate Kevin Warsh to lead the...
SoFi posts record quarterly revenue, adds over 1M members
05:57am, Friday, 30'th Jan 2026
SoFi Technologies Inc. (NASDAQ: SOFI) reported its highest-ever quarterly revenue and membership growth on Friday thanks to strong demand across its lending...
Chevron delivers mixed earnings for fourth quarter
05:19am, Friday, 30'th Jan 2026
Chevron Corporation (NYSE:CVX, XETRA:CHV) posted mixed earnings for the fourth quarter, with profit above Wall Street estimates but revenue falling short....
Dow likely to extend record while tech stocks flounder
03:00am, Friday, 12'th Dec 2025
8am: Rotation notches up a gear US stock benchmark futures were mixed ahead of Friday's open as investors shied away from tech stocks and focused on...
FDA backs Imugene's azer-cel treatment plan - ICYMI
01:42am, Friday, 12'th Dec 2025
Imugene Ltd (ASX:IMU, OTC:IUGNF) earlier this week confirmed that the US FDA has fully supported the company's Phase 1B study data for its CAR-T cell therapy, azer-cel. The company said the regulator
Pinterest downgraded, price target lowered on emerging AI risks
07:47am, Monday, 08'th Dec 2025
Pinterest Inc (NYSE:PINS) has been downgraded by Wedbush analysts to a ‘Neutral’ rating from ‘Outperform,’ with the firm citing emerging risks from AI and...
Imugene secures FDA backing for Azer-cel registration pathway
07:32am, Monday, 08'th Dec 2025
Imugene Ltd (ASX:IMU, OTC:IUGNF) has won crucial backing from the US Food and Drug Administration (FDA), with written minutes from a recent Type C meeting...
